Humacyte, Inc. HUMA
0.44 USD +0.04 (+10.65%)
At closeNov 3, 2026, 7:57 PM EST
0.45 +0.01 +2.16%
After hours · Nov 3, 7:57 PM ET
0.391 Day range 0.4452
0.337 52-week range 1.56
- YTD
- -54.16%
- 1 year
- -72.30%
News
benzinga.com Humacyte Announces Three Presentations At American Heart Association Scientific Sessions, November 6–9; Two Additional Presentations To Cover First-In-Human Phase 2a Study Design And Preclinical Results For Its Investigational Coronary Tissue Engineered Vessel AHA Scientific Sessions is one of the world’s largest gatherings of cardiovascular clinicians and scientists. Humacyte’s presentations include an invited talk by the company’s Founder, President and…
globenewswire.com Humacyte Innovative Research in Coronary Bypass and Vascular Regeneration to be Highlighted at American Heart Association Scientific Sessions 2026 – Founder & CEO Laura Niklason, M.D., Ph.D., to deliver invited talk on engineering the microenvironment to accelerate vascular regeneration.
globenewswire.com Humacyte To Announce 2026 Third Quarter Financial Results and Provide Business Update on November 10, 2026 DURHAM, N.C, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at…
zacks.com Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights Humacyte, Inc. (HUMA) concluded the recent trading session at $0.41, signifying a -13.01% move from its prior day's close.
globenewswire.com Humacyte Strengthens Intellectual Property Portfolio with Issuance of New U.S. Patent Covering Symvess and Other Bioengineered Tissues – Patent provides coverage into 2043 for key aspects of how Symvess is manufactured, sterilized, stored and shipped. DURHAM, N.C.
defenseworld.net Humacyte, Inc. (NASDAQ:HUMA) Stock Now Rated “Moderate Buy” by Sell-Side Analysts Shares of Humacyte, Inc. (NASDAQ: HUMA - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight research firms that are covering the company, MarketBeat Ratings reports.…
benzinga.com Humacyte Presents Interim Results From V012 Phase 3 Clinical Trial Of Acellular Tissue Engineered Vessel In Arteriovenous Access For Female Hemodialysis Patients, At ASN Kidney Week 2026 - The presenter, Dr. Roy-Chaudhury said, "These results give the nephrology community a strong reason to rethink our approach to access decisions for women and, once approved by the FDA, to consider…
globenewswire.com Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner - The presenter, Dr. Roy-Chaudhury said, “These results give the nephrology community a strong reason to rethink our approach to access decisions for women and, once approved by the FDA, to consider…
zacks.com Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today Humacyte, Inc. (HUMA) closed at $0.41 in the latest trading session, marking a +1.28% move from the prior day.
zacks.com Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note In the most recent trading session, Humacyte, Inc. (HUMA) closed at $0.4, indicating a -6.5% shift from the previous trading day.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 11.0% to $0.17 during Friday's after-market session. The company's market cap stands at $2.4 million. Lexaria Bioscience…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Regencell Bioscience (NASDAQ:RGC) stock increased by 30.4% to $10.58 during Thursday's regular session. The company's market cap stands at $4.0 billion. SenesTech (NASDAQ:SNES) stock rose…- benzinga.com Humacyte Reports Accelerating Commercial Adoption, Reports 44% Increase In Hospitals Ordering Symvess To 49 In Q3 2026 – Hospitals that have ordered Symvess® increased 44% during the third quarter, from 34 at the end of the second quarter to 49 as of September 30, 2026.– Commercial momentum continues to build, driven…
globenewswire.com Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals – Hospitals that have ordered Symvess® increased 44% during the third quarter, from 34 at the end of the second quarter to 49 as of September 30, 2026. – Commercial momentum continues to build,…
zacks.com Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know Humacyte, Inc. (HUMA) concluded the recent trading session at $0.36, signifying a -7.88% move from its prior day's close.
benzinga.com Barclays Initiates Coverage On Humacyte with Equal-Weight Rating, Announces Price Target of $0.5 Barclays analyst Christopher Pasquale initiates coverage on Humacyte (NASDAQ:HUMA) with a Equal-Weight rating and announces Price Target of $0.5.
zacks.com Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade Humacyte, Inc. (HUMA) concluded the recent trading session at $0.48, signifying a -4.26% move from its prior day's close.
zacks.com Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note Humacyte, Inc. (HUMA) concluded the recent trading session at $0.5, signifying a -2.86% move from its prior day's close.
globenewswire.com Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at…
zacks.com Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.56, representing a -2% change from its previous close.
zacks.com Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know Humacyte, Inc. (HUMA) reached $0.59 at the closing of the latest trading day, reflecting a +2.23% change compared to its last close.
zacks.com Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic? When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often…
globenewswire.com Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at…
benzinga.com Humacyte Receives FDA Authorization To Extend The Expiration Dating Period For Symvess From 18 To 36 Months Extension for Symvess (acellular tissue engineered vessel-tyod, or ATEV) from 18 months to 36 months when stored refrigerated at 2°C to 8°C (36°F to 46°F).The expiration dating extension is supported…
globenewswire.com Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months – FDA authorizes extension of Symvess expiration dating from 18 months to 36 months – – Extended shelf life supported by additional stability data demonstrating Symvess continues to meet all…
businesswire.com Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues…- benzinga.com Humacyte Confirms Plans For ATEV Supplemental BLA Filing – Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 –– Supplemental BLA will be supported by results from three Phase…
globenewswire.com Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions – Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 –
benzinga.com Humacyte Announces Symvess Acellular Tissue Engineered Vessel-Tyod Now Being Used By Arizona Surgeons Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered human tissues, today announced that Symvess, acellular tissue engineered vessel-tyod, is now being…- benzinga.com Benchmark Maintains Speculative Buy on Humacyte, Lowers Price Target to $1 Benchmark analyst Bruce D. Jackson maintains Humacyte (NASDAQ:HUMA) with a Speculative Buy and lowers the price target from $2 to $1.
benzinga.com Humacyte Q2 EPS $(0.16) Misses $(0.10) Estimate, Sales $406.000K Miss $1.116M Estimate Humacyte (NASDAQ:HUMA) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.10) by 60 percent. This is a 33.33 percent increase over losses of $(0.24) per…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $20.3 million. Humacyte (NASDAQ:HUMA) shares moved upwards by 5.45% to…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com Earnings Scheduled For May 13, 2026 
benzinga.com This Rockwell Automation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Top Wall Street analysts changed outlook on top names. Needham downgrades CNTA, Baird downgrades PHR.- benzinga.com Earnings Scheduled For March 27, 2026
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Earnings Scheduled For November 12, 2025
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Russell 2000 Hits All-Time Highs: 8 Stocks Power Small-Cap Comeback Small-cap benchmark Russell 2000 ETF hits record high after Fed cuts rates, hinting at more cuts. Small caps rally 43% since tariff-driven selloff.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Earnings Scheduled For August 11, 2025
benzinga.com GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday 
benzinga.com Gold Falls 1%; ProKidney Shares Spike Higher